Business Wire - Eli Lilly and Company: Strattera Prescriptions Double in Three-Month Period; Nonstimulant ADHD Medication’s Market Share Climbs to 16.3 Percent in September
Business Editors/Health/Medical Writers
INDIANAPOLIS–(BUSINESS WIRE)–Oct. 16, 2003
In its first nine months on the market, doctors have written more than 2 million prescriptions for Strattera(R) (atomoxetine HCl), the only nonstimulant medicine approved for the treatment of Attention-Deficit/Hyperactivity Disorder, Eli Lilly and Company (NYSE:LLY) announced today.
That’s up from roughly 1 million prescriptions in six months, which gave Strattera the fastest launch ever for a new ADHD medicine, according to data from IMS Health(1), which tracks the industry. Growth was especially strong among pediatricians and primary care physicians, who are on the front line of treating people with ADHD.
Most Popular
5 Regular Mistakes In Public Speaking
10 Jobs That Pay $30 An Hour
Interpersonal Communication: Styles Of Conflict
13 Job Interview Mistakes To Avoid
Business Plan Sample
“Strattera, by providing continuous relief of ADHD symptoms in a nonstimulant medication, clearly fills a previously unmet need for physicians and patients,” said Gino Santini, Lilly’s president of U.S. operations. “This tremendous growth in prescriptions during the summer months, when ADHD prescriptions typically decline, shows how quickly Strattera has become an important first-line treatment option for children and adults with ADHD.”
As of September 30, Strattera’s market share rose to 16.3 percent from 12.9 percent in June, according to IMS Health data. By comparison, Concerta(R) had 24.0 percent market share in September and Adderall XR(R) had 22.4 percent market share.
Through September 30, 2.149 million prescriptions for Strattera were dispensed by pharmacies, according to IMS Health data. Through June 30, 1.09 million prescriptions were dispensed.
About ADHD
ADHD affects 3-7 percent of school-age children(2) and manifests itself in levels of attention, concentration, activity, distractibility, and impulsivity that are inappropriate to the child’s age.(3) In addition, 60 percent of children with the disorder carry their symptoms into adulthood.(4) Experts estimate 4 percent of adults in the United States, more than 8 million people, have ADHD.(5)
About Strattera
The U.S. Food and Drug Administration approved Strattera on November 26, 2002 for the treatment of ADHD in children, adolescents and adults. Strattera, a selective norepinephrine reuptake inhibitor, works differently than other FDA-approved treatments for the disorder, all of which are stimulants. It is not known precisely how Strattera reduces ADHD symptoms, but scientists believe it works by blocking or slowing reabsorption of norepinephrine, a chemical in the brain considered important in regulating attention, impulsivity and activity levels. This keeps more norepinephrine at work in the spaces between neurons in the brain. Improved efficiency in the norepinephrine system is associated with improvement in symptoms of ADHD (Plitzka, 1996)
Strattera should not be taken at the same time as, or within two weeks of taking, a monoamine oxidase inhibitor, or by patients with narrow angle glaucoma. Patients with a history of high or low blood pressure, increased heart rate, or any heart or blood vessel disease should tell their doctor before taking Strattera. Strattera has not been tested in children less than 6 years of age or in geriatric patients. Some children may lose weight when starting treatment with Strattera. As with all ADHD medications, growth should be monitored during treatment.
Most people in clinical studies who experienced side effects were not bothered enough to stop using Strattera. The most common side effects in children and adolescents in medical studies were upset stomach, decreased appetite, nausea and vomiting, dizziness, tiredness and mood swings. In adults, the most common side effects were constipation, dry mouth, nausea, decreased appetite, dizziness, problems sleeping, sexual side effects, problems urinating and menstrual cramps.
About Lilly
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world’s most urgent medical needs.
For full prescribing information visit www.strattera.com.
(1) IMS Health, NPA Plus(TM), 2003.
(2) American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, fourth edition, text revision. Washington, DC, American Psychiatric Association, 2000.
(3) American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, fourth edition. Washington, DC, American Psychiatric Association, 1994.
(4) American Psychiatric Association: DSM-IV-TR.2000.85-93
Schweitzer JB, et al. Attention-deficit/hyperactivity disorder. Med Clin of North Am. 2001; 85(3):757-777
(5)Heiligenstein, et al. 1997
United States Census 2000. Census 2000 Summary File 1 (SF 1) 100-Percent Data
COPYRIGHT 2003 Business Wire
COPYRIGHT 2008 Gale, Cengage Learning
